I recommend waiting for a better discount before investing in Bioventus Inc. (BVS).

After finishing at $1.90 in the prior trading day, Bioventus Inc. (NASDAQ: BVS) closed at $1.88, down -1.05%. In other words, the price has decreased by -$0.0200 from its previous closing price. On the day, 979961 shares were traded. BVS stock price reached its highest trading level at $1.9200 during the session, while it also had its lowest trading level at $1.8200.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

Our goal is to gain a better understanding of BVS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.78.

Upgrades & Downgrades

On November 09, 2022, Canaccord Genuity Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $18 to $6.

On March 15, 2022, Craig Hallum started tracking the stock assigning a Buy rating and target price of $30.Craig Hallum initiated its Buy rating on March 15, 2022, with a $30 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 04 when D’Adamio Anthony sold 16,016 shares for $11.19 per share. The transaction valued at 179,238 led to the insider holds 40,132 shares of the business.

Nosenzo John sold 65,963 shares of BVS for $733,502 on Apr 04. The Chief Commercial Officer now owns 83,932 shares after completing the transaction at $11.12 per share. On Apr 04, another insider, Pavesio Alessandra, who serves as the SVP & Chief Science Officer of the company, sold 32,997 shares for $11.17 each. As a result, the insider received 368,425 and left with 148,309 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.30 while its Price-to-Book (P/B) ratio in mrq is 0.26.

Stock Price History:

Over the past 52 weeks, BVS has reached a high of $15.57, while it has fallen to a 52-week low of $1.65. The 50-Day Moving Average of the stock is 6.3862, while the 200-Day Moving Average is calculated to be 9.2645.

Shares Statistics:

The stock has traded on average 297.86K shares per day over the past 3-months and 1.2M shares per day over the last 10 days, according to various share statistics. A total of 61.48M shares are outstanding, with a floating share count of 52.20M. Insiders hold about 4.50% of the company’s shares, while institutions hold 68.70% stake in the company. Shares short for BVS as of Oct 13, 2022 were 2M with a Short Ratio of 1.99M, compared to 1.85M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.24% and a Short% of Float of 5.11%.

Earnings Estimates

Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of $0.12 for the current quarter, with a high estimate of $0.14 and a low estimate of $0.09, while EPS last year was $0.25. The consensus estimate for the next quarter is $0.24, with high estimates of $0.26 and low estimates of $0.22.

Analysts are recommending an EPS of between $0.53 and $0.49 for the fiscal current year, implying an average EPS of $0.51. EPS for the following year is $0.62, with 5 analysts recommending between $0.68 and $0.55.

Revenue Estimates

4 analysts predict $141.59M in revenue for the current quarter. It ranges from a high estimate of $144.48M to a low estimate of $139.1M. As of the current estimate, Bioventus Inc.’s year-ago sales were $102.23M, an estimated increase of 38.50% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $154.52M, an increase of 18.50% less than the figure of $38.50% in the same quarter last year. There is a high estimate of $156.39M for the next quarter, whereas the lowest estimate is $152.7M.

A total of 5 analysts have provided revenue estimates for BVS’s current fiscal year. The highest revenue estimate was $556M, while the lowest revenue estimate was $549.4M, resulting in an average revenue estimate of $553.86M. In the same quarter a year ago, actual revenue was $430.9M, up 28.50% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $614.86M in the next fiscal year. The high estimate is $622.8M and the low estimate is $608.63M. The average revenue growth estimate for next year is up 11.00% from the average revenue estimate for this year.